Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices
Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices
复制标题
DOI：
10.1016/j.vaccine.2010.01.032
复制
发表时间：
2010-03-24
期刊：
影响因子：
5.5
通讯作者：
Jirathitikal, Vichai
中科院分区：
文献类型：
--
作者：
Bourinbaiar, Aldar S.;Jirathitikal, Vichai
通过接种疫苗来调节炎症反应在动脉粥样硬化和肥胖的动物模型中显示出了希望--这是心血管疾病的主要危险因素。13名志愿者每天口服含有来自猪脂肪组织的混合抗原的片状制剂V-6，持续3个月。总胆固醇和低密度脂蛋白水平与基准值没有变化；分别为193.4比191.8(p=0.75)和113.8比117.2(p=0.18)。甘油三酯水平下降26.1%，从163mgdL降至120.5 mg/dL(p=0.29)。13例患者中有12例高密度脂蛋白从38.6mgdL上升到48.5mgdL(p=0.000002)，上升25.9%。尽管V6对体重和体重指数的影响微乎其微，分别为67.87vs66.58 kg(-1.9%；p=0.46)和26.25vs25.75 kg/m(2)(-1.9%；p=0.35)，但腰围(-7.6%；p=0.002)、臂中部(-3.3%；p=0.049)和大腿(-7.6%；p=0.0003)都有显著的下降。血压、收缩压和舒张压未受影响，分别为115.6比121(p=0.2)和77.1vs83(p=0.55)。肝脏ALT、AST酶无明显变化。BUN略有升高，但仍在正常范围内；肌酐下降，分别为0.877和0.842 mg/dL(P=0.02)。空腹血糖水平也在正常范围内，即94.8vs98.8(p=0.04)。全血细胞分析显示除血红蛋白13.25-13.19g/dL略有下降(p=0.0004)外，其他变化不大，但其单位红细胞数量从25.62pg/cell增加到26.42pg/cell(p=0.000003)。平均红细胞大小从78.5fl增加到80.0fl(p=0.00009)，但与细胞大小相关的血红蛋白浓度没有变化(p=0.2fl)。红细胞压积和红细胞计数略有下降，但在正常范围40.7-40.2%(p=0.02)和5.22-5.05×10(6)个/mm(3)(p=0.002)。每毫米(3)上移的血小板数分别为2.471和2.921×10(5)(p=0.009)。白细胞计数和白细胞、中性粒细胞百分率未受影响。促炎症的嗜酸性粒细胞从4.0%下降到2.4%(p=0.29)。这些结果表明，V6是安全的，有望成为一种抗动脉粥样硬化和超重/肥胖的免疫干预。(C)2010爱思唯尔有限公司。保留所有权利。
Modulation of the inflammatory response through vaccination has shown promise in animal models of atherogenesis and obesity-main risk factors for cardiovascular diseases. Tableted preparation, V-6, containing pooled antigens derived from pig adipose tissue was administered per os daily to 13 volunteers for 3 months. Total cholesterol and LDL levels have not changed from the baseline value; 193.4 vs 191.8 (p = 0.75) and 113.8 vs 117.2 (p = 0.18), respectively. Triglyceride levels declined by 26.1% from 163 to 120.5 mg/dL (p = 0.29). HDL increased by 25.9% from 38.6 to 48.5 mg/dL (p = 0.000002) in 12 out 13 patients. Despite negligible effect of V6 on weight and body mass index, i.e., 67.87 vs 66.58 kg (-1.9%; p = 0.46) and 26.25 vs 25.75 kg/m(2) (-1.9%; p = 0.35), statistically significant reduction in waist (-7.6%; p = 0.002), mid-arm (-3.3%; p = 0.049), and thigh (-7.6%; p = 0.0003) circumferences were observed. Blood pressure systolic and diastolic values were not affected, i.e., 115.6 vs 121 (p = 0.2) and 77.1 vs 83 (p = 0.55). No changes were observed in liver ALT and AST enzymes. Creatinine decreased; 0.877 vs 0.842 mg/dL (p = 0.02), while BUN has shown slight increase; 14.8 vs 16.1 mg/dL (p = 0.03) but within normal range. Fasting blood sugar levels were also within normal range, i.e., 94.8 vs 98.8 (p = 0.04). Complete blood cell analysis has not revealed any change except slight decrease in hemoglobin 13.25-13.19 g/dL (p = 0.0004), but its amount per red blood cell (MCH) increased from 25.62 up to 26.42 picograms/cell (p = 0.000003). The average red blood cell size (MCV) increased from 78.5 to 80.0 fl (p = 0.00009) but hemoglobin concentration relative to size of the cell (MCHC) has not changed (p = 0.2). Hematocrit and red blood cells count decreased slightly, but within normal range 40.7-40.2% (p= 0.02) and 5.22-5.05 x 10(6) cells/mm(3) (p = 0.002). The number of platelets moved upward, 2.471 vs 2.921 x 10(5) per mm(3) (p = 0.009). The white blood cells count and percent of leukocytes and neutrophils were not affected. Pro-inflammatory eosinophils declined from 4.0% down to 2.4% (p = 0.29). These results show that V6 is safe and holds a promise as an anti-atherogenic and overweight/obesity immune intervention. (C) 2010 Elsevier Ltd. All rights reserved.